Biocartis completes €34.5m Series D equity fundraising

Molecular diagnostics company Biocartis, which develops platforms and clinically relevant oncology assays, has completed a €34.5m (£28m) Series D equity fundraising entirely backed by existing investors.

Biocartis provides research and diagnostic systems with simultaneous multiplex detection and simplified workflows that are claimed to require less hands-on time and to improve sample consumption.

In addition, the company develops assays that have high clinical utility and excellent health economic value.